Stockwinners Market Radar for July 17, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Boeing (BA) projected demand for more than 41,000 new airplanes through 2041 as it released its 2022 Commercial Market Outlook, the company's annual long-term forecast, in advance of the Farnborough International Airshow. "The CMO forecasts a market value of $7.2 trillion for new airplane deliveries, with the global fleet increasing by 80% through 2041 compared to 2019 pre-pandemic levels. Approximately half of passenger jet deliveries will replace today's models, improving the global fleet's fuel efficiency and sustainability. In addition, Boeing Global Services forecasts $3.6 trillion in demand in its market segments over the same time period, including strong demand for maintenance and modifications such as converted freighters; digital solutions that increase efficiency and reduce cost; and effective training to enable the supply of pilots and technicians," the company stated. 2. According to The Times' Sabah Meddings, Starbucks (SBUX) is exploring a potential sale of its U.K. operations as it faces rising costs and competition from newer operators. It is understood that the world's largest coffee chain has asked its adviser, Houlihan Lokey, to canvass interest for its U.K. business, which oversees more than 1,000 coffee shops and employs 4,000 people. Of these, about 300 stores are operated by Starbucks, with the remainder owned and run by franchisees who pay royalties to the parent company, the author noted. Meanwhile, Starbucks said in a statement that it is not in a formal sale process for its U.K. business, according to Reuters. 3. Estee Lauder (EL) is in the beauty business-and its stock is starting to look like a beautiful buy, Jacob Sonenshine wrote in this week's edition of Barron's. With the stock down so much this year, worries may be already reflected in the shares, and it wouldn't take much good news to send them higher, the author contended. That good news could come from China, which is finally starting to reopen, even if it's coming in fits and starts. Americans, meanwhile, continue to return to the office, to social gatherings, and to everyday life, the publication added. 4. Marvel and Disney's (DIS) "Thor: Love and Thunder" won this weekend's domestic box office with another $46M in its second outing. The movie's domestic total stands at $233M, while its global ticket sales are nearing the $500M mark. Audiences gave "Thor: Love and Thunder" a B+ CinemaScore. 5. Mattel (MAT), AvalonBay Communities (AVB), Equity Residential (EQR), Camden Property Trust (CPT), Mid-America Apartment Communities (MAA), Apartment Income REIT (AIRC), and UDR (UDR) saw positive mentions in this week's edition of Barron's.

14:55 EDT Iveric Bio announces post-hoc analysis from GATHER1 clinical trial of Zimura - Iveric bio announced that in a post-hoc analysis from the GATHER1 clinical trial, Zimura showed a reduction of geographic atrophy lesion growth, compared to sham, across all distances from the foveal center point. The analysis reported that approximately 84% of patients had lesions within 500 microns of the foveal center point at baseline and that approximately 28% of patients had lesions within 100 microns of the foveal center point at baseline. These findings were generally balanced across all treatment arms and their corresponding sham control groups in the trial. The accompanying graphs summarize the results of this post-hoc analysis. The most frequently reported ocular adverse events were related to the injection procedure. There were no drug related adverse events such as inflammation or endophthalmitis reported in GATHER1. No additional safety analysis was performed as part of this post-hoc analysis.